Drug-drug interaction with oral antivirals for the early treatment of COVID-19

Drug-drug interaction with oral antivirals for the early treatment of COVID-19

Bibliographic Details
Main Authors:	Alpo Vuorio, Frederick Raal, Petri T. Kovanen
Format:	Article
Language:	English
Published:	Elsevier 2023-02-01
Series:	International Journal of Infectious Diseases
Subjects:	Statins Atherosclerotic cardiovascular disease COVID-19 Nirmatrelvir/ritonavir
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971222006324

Similar Items

Drug-drug interaction with oral antivirals for early treatment of COVID-19 – Authors’ reply
by: Carsten Schade Larsen
Published: (2023-01-01)

Familial Hypercholesterolemia Patients with COVID-19—Effective Cholesterol-Lowering Therapy is Urgent both during and after Infection
by: Alpo Vuorio, et al.
Published: (2022-12-01)

Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
by: Karolina Akinosoglou, et al.
Published: (2022-11-01)

Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19
by: Carsten Schade Larsen
Published: (2022-09-01)

Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong
by: Yue Yat Harrison Cheung, et al.
Published: (2024-01-01)

Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world studyResearch in context
by: Shuxia Wang, et al.
Published: (2024-03-01)

Nirmatrelvir–Ritonavir Reduced Mortality in Hospitalized Patients with COVID-19 During the Omicron Outbreak: Real-World Evidence from Beijing
by: Zhang Y, et al.
Published: (2024-04-01)

Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review
by: Sydney Paltra, et al.
Published: (2024-01-01)

Long-Term Cardiovascular and Cerebrovascular Challenges Posed by COVID-19 in Patients With Familial Hypercholesterolemia
by: Alpo Vuorio, et al.
Published: (2022-05-01)

Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment
by: Alpo Vuorio, et al.
Published: (2023-12-01)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
by: Jiayue Lu, et al.
Published: (2023-05-01)

SARS-CoV-2 reinfection: Adding insult to dysfunctional endothelium in patients with atherosclerotic cardiovascular disease
by: Petri T. Kovanen, et al.
Published: (2023-09-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022-12-01)

Joint analysis of vaccination effectiveness and antiviral drug effectiveness for COVID-19: a causal inference approach
by: Yue Yat Harrison Cheung, et al.
Published: (2024-06-01)

Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence
by: Lavanya Visvabharathy, et al.
Published: (2022-09-01)

Potential herb–drug interactions between anti-COVID-19 drugs and traditional Chinese medicine
by: Ling Ye, et al.
Published: (2023-09-01)

Post nirmatrelvir/ritonavir erythema multiforme in a patient with coronavirus disease infection
by: José Wagner Leonel Tavares-Júnior, et al.
Published: (2023-06-01)

The Development of an Oral Solution Containing Nirmatrelvir and Ritonavir and Assessment of Its Pharmacokinetics and Stability
by: Lili Wang, et al.
Published: (2024-01-01)

The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients
by: Xiang Z, et al.
Published: (2024-01-01)

Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients
by: Peng Su, et al.
Published: (2024-01-01)

The Clinical Efficacy and Safety of Anti-Viral Agents for Non-Hospitalized Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
by: Chih-Cheng Lai, et al.
Published: (2022-08-01)

Case report: Paralytic ileus resulted from nirmatrelvir/ritonavir-tacrolimus drug-drug interaction in a systemic lupus erythematosus patient with COVID-19
by: Wei Zhang, et al.
Published: (2024-03-01)

Antiviral Treatment in Older Chinese Patient with SARS-CoV-2 and Influenza A Virus Co-Infection: A Case Series
by: Yang W, et al.
Published: (2023-07-01)

Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer
by: Kaleem Anwar, PharmD, et al.
Published: (2023-02-01)

Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19
by: Hu CY, et al.
Published: (2023-12-01)

Impact of Early SARS-CoV-2 Antiviral Therapy on Disease Progression
by: Andrea De Vito, et al.
Published: (2022-12-01)

Pharmacokinetics Profile and Genetics of Double Antiviral Therapy with Remdesivir and Nirmatrelvir/Ritonavir for Prolonged COVID-19 in Patients Treated with Rituximab: A Real-Life Study and Literature Review
by: Ilaria De Benedetto, et al.
Published: (2024-01-01)

Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
by: Mei-Ping Chen, et al.
Published: (2024-02-01)

A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient
by: Chien-Ming Lo, et al.
Published: (2024-03-01)

Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease
by: Marta Colaneri, et al.
Published: (2024-03-01)

The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data
by: Vasilios Petrakis, et al.
Published: (2023-04-01)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
by: Yuan-Pin Hung, et al.
Published: (2022-02-01)

Update on COVID-19 Therapy in Pediatric Age
by: Susanna Esposito, et al.
Published: (2022-12-01)

Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment
by: Angioletta Lasagna, et al.
Published: (2022-10-01)

Efficacy and safety of Nirmatrelvir/Ritonavir for treating the Omicron variant of COVID-19
by: Chaochao Qiu, et al.
Published: (2023-07-01)

Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
by: Vassiliki Spiliopoulou, et al.
Published: (2023-03-01)

Wildfire smoke exposure and cardiovascular disease—should statins be recommended to prevent cardiovascular events?
by: Alpo Vuorio, et al.
Published: (2023-09-01)

Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting
by: Wang Chun Kwok, et al.
Published: (2023-02-01)

Identifying Innate Resistance Hotspots for SARS-CoV-2 Antivirals Using In Silico Protein Techniques
by: Stephanie Portelli, et al.
Published: (2023-08-01)

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study
by: Zhao X, et al.
Published: (2023-09-01)